Granix® (tbo-filgrastim) – Expanded indication and new warnings
July 31, 2018 - The FDA announced the approval of Teva’s Granix (tbo-filgrastim), for the treatment of adult and pediatric patients 1 month and older for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Top